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Abstract
Background: Infectious disease screening of migrants at increased risk is a feature of national infection prevention
and control measures. Asylum seekers in Finland are offered screening of tuberculosis (TB), hepatitis B, human
immunodeficiency virus infection (HIV) and syphilis based on individual risk assessment. We aimed to evaluate the
public health response to a large influx of asylum seekers to Finland in 2015–2016 with respect to national guidelines
on initial health services and infectious disease screening.
Methods: We used immigration and healthcare procurement data for all 38,134 asylum seekers to Finland during
2015–2016 to assess the implementation, timing and yields of infectious disease screening.
Results: The coverage of pulmonary TB screening was 71.6% [95% CI 71.1–72.0%] and that of hepatitis B, HIV or syphilis 60.
6% [60.1–61.1%] among those eligible for screening. The estimated average delay from arrival to pulmonary TB screening
was 74 days for adults and 43 days for children. Delay to hepatitis B, HIV and syphilis screening was 91 days for adults and
47 days for children. The seroprevalence of hepatitis B surface antigen positivity was 1.4% [95% CI 1.3–1.6%], HIV 0.3% [95%
CI 0.1–0.4%] and Treponema pallidum specific antibodies 1.0% [95% CI 0.8–1.1%]. Data did not allow assessment of yields of
pulmonary TB screening.
Conclusions: Up to one third of asylum seekers were not reached by screening and screenings were delayed from target
timeframes. Children, as a vulnerable population, were screened earlier than adults. To ensure higher screening coverage,
infectious disease risks should be reassessed and screening completed at contacts to healthcare during the post-asylum
phase of integration. The large influx of asylum seekers to Finland in 2015–2016 tested the country’s public
health preparedness. After action reviews of the public health response to the large migrant influx such as
screening implementation can be used for evidence-based improvement of public health preparedness and
guidelines for initial health services and infectious disease screening.
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Background
Migrants may have an increased risk for certain infec-
tious diseases, including tuberculosis (TB), hepatitis and
human immunodeficiency virus infection (HIV), de-
pending on factors such as the prevalence of the disease,
the living conditions and potential healthcare service
disruptions in their country of origin and during transit,
as well as individual risk behaviours [1]. European mem-
ber states of World Health Organization (WHO) have
committed themselves to ensuring the necessary capaci-
ties to address communicable diseases among migrant
populations [2]. Several European countries, including
Finland, have adopted screening protocols for refugees
and asylum seekers [3–5], with substantial variation be-
tween countries and regions. Screening of infectious dis-
eases aims to detect a disease at an early stage, and thus
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to protecting both the individual and the population [6].
Screening should be acceptable, cost-effective and
follow-up services made available. [7]
An asylum seeker is a person seeking international
protection from a foreign country and awaiting the deci-
sion on their application for refugee status [8].
In the autumn of 2015, Europe experienced a large-scale
arrival of asylum seekers, mainly from Middle Eastern
countries and the Horn of Africa [9, 10]. The nearly
ten-fold increase in asylum seekers to Finland was among
the highest in Europe [11, 12]. This “migration crisis” trig-
gered the largest domestic relief operation and public
health response since World War II [13].
The public health response to a large influx of asylum
seekers, and specifically screening for infectious diseases, is
an important dimension of national public health emer-
gency preparedness [14]. The public health response deter-
mines the health and human rights outcomes for migrants,
as well as the host population [9]. Ensuring the highest at-
tainable health for migrants requires an effective health sys-
tem response and removal of barriers to healthcare [15].
Within the WHO Health 2020 framework, Public Health
Aspects of Migration in Europe (PHAME) project [9] and
International Health Regulations (IHR 2005), countries of
the WHO Europe region are assessing and evaluating their
capacities to respond to the healthcare needs of a large in-
flux of asylum seekers.
While there are several reports on the screening yields
of infectious diseases among newly-arrived asylum seekers
to Europe [16–20], only a few [21, 22] have focused on de-
scribing the implementation of the public health response.
As dimensions of the public health response, we aimed to
evaluate the implementation of the national guidelines, in-
cluding screening coverage, timing, assessment of vulner-
ability and screening yields, during the large influx of
asylum seekers to Finland in 2015–2016.
Methods
Organisation of asylum seekers’ healthcare in Finland
The Finnish Immigration Service (Migri) falls under the
Ministry of the Interior and is in charge of the asylum
process in Finland. The Migri is also responsible for or-
ganizing sufficient reception center capacity and coord-
ination, planning and supervision of the practical aspects
of healthcare for asylum seekers in Finland.
All registered asylum seekers in Finland have a desig-
nated reception centre which organises their reception
services including housing, board, and health and social
services. Private for-profit and not-for-profit organisa-
tions are amongst the providers of reception services.
Typically, asylum seekers are first accommodated in
so-called transit centres for a period of days to weeks be-
fore they are assigned to a reception centre for longer
term settlement, until their asylum claim has been
processed. Asylum seekers who live in private housing
are also assigned to receive services from a particular re-
ception centre.
According to the Act on the Reception of Asylum
Seekers (746/2011), adult asylum seekers in Finland are
entitled to urgent and necessary healthcare. Asylum-seek-
ing children under 18 years of age are entitled to the same
level of care as permanent residents. Registered nurses
who work in the transit and reception centres coordinate
the organisation of health services for asylum seekers. The
nurses have a public health, midwifery or specialised care
background. Nurses initiate the voluntary health examina-
tions at the centres and provide primary level nursing;
however, other healthcare services, including the actual
screenings, are purchased from public or private health
services.
Infectious disease screening among asylum seekers
In Finland, the legal obligation for the infectious disease
control lies with the 311 municipalities, 20 hospital dis-
tricts and 6 Regional State Administrative Agencies. The
Ministry for Social Affairs and Health (STM) is respon-
sible for the overall management and takes the lead in
public health emergencies.
According to STM guidelines [23], asylum seekers and
refugees in Finland are offered multiphasic selective
screening of TB, hepatitis B, HIV and syphilis based on
an individual risk assessment (Table 1). A symptom-
based questionnaire is used to identify those with pos-
sible symptoms of active TB. Pulmonary TB is screened
with a chest X-ray (CXR) from two projections right
after the health examination, which is arranged within 2
weeks of arrival. Children under 7 years of age who have
not received a Bacillus Calmette-Guérin vaccine are also
screened for latent and extra-pulmonary TB. The
screening of hepatitis B, HIV, and syphilis is arranged
within 3 months of arrival. Children under 16 years of
age are screened for intestinal protozoa and helminth
eggs within 3 months of arrival. Participation in screen-
ings is voluntary and a written informed consent is ob-
tained from participants or their legal representatives.
The reception centre nurse assesses each individual’s
infectious disease risk based on relevant disease epi-
demiology in the countries of origin and transit, as well
as individual medical history and risk behaviours. Profes-
sional interpreters are used if necessary. Priority is given
to individuals in vulnerable situations or presenting with
symptoms; children, pregnant women, and disabled per-
sons are referred to a doctor’s appointment. The Na-
tional Institute for Health and Welfare publishes
guidance documents to support the decision making and
risk assessment processes, including information on the
global infectious disease prevalence [24].
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Study design
We performed a cross-sectional retrospective register-based
study to by comparing data from two different sources: the
immigration register and the healthcare procurement regis-
ter. We were not able to link the two data sources on an in-
dividual level and hence the data were analysed in parallel.
The immigration register included monthly information on
the nationalities and age groups of asylum seekers. Health-
care procurement register collected monthly information on
the number and kind of procurements for different age
groups. Migri had contracted out the infectious disease
screenings of asylum seekers to two national private service
providers, who the reception centres purchase the screening
services from. Since asylum seekers are generally not
assigned a personal identification number, which would fa-
cilitate the use of data from the patient information systems,
and since the reception centres do not consistently report
screening findings, procurement data were the only feasible
source with which to assess screening coverage and yields.
All asylum seekers to Finland in 2015–2016 were in-
cluded in the analyses. Individuals with missing informa-
tion on nationality or unknown nationality were excluded.
Data for the study were collected from January 1st 2015
till December 31st 2016. Results were stratified by age. In-
dividuals under 18 year of age were considered children.
Outcomes
Screening coverage was calculated as the number of
screenings performed (numerator) against the number
of asylum seekers eligible for screening (denominator).
Eligibility for screening of pulmonary TB and syphilis
was determined according to the national guidelines
after assuming the country of nationality as the country
of origin [23, 24]. Syphilis screening was used as an indi-
cator for any blood screening performed since, according
to national guidelines, syphilis screening is recom-
mended whenever either hepatitis B or HIV is screened.
Timing of screening was assessed by comparing the
dates of arrival to the dates of screening performed strati-
fied by age group. As we were not able to link the data at
individual level, we calculated the median and average
dates of arrival and screening at population level. The
delay to screening was calculated as the difference be-
tween average dates of arrival and screening. Dynamics of
achieving the screening coverage was depicted visually by
plotting the cumulative absolute number of CXR and
syphilis serology screenings performed for adults and chil-
dren against the number of new asylum seekers to Finland
during 2015–2016 from screening-eligible countries
(Fig. 1). To portray the delays of performed screenings
against the target timeframes as per national guidelines,
we plotted the cumulative relative proportion of screen-
ings performed out of all screenings performed against the
cumulative relative proportion of asylum seekers eligible
for screening adjusted with the target timeframes for
screening (Fig. 2). Screenings were considered delayed
when the plot for cumulative proportion of screenings
performed took place later than the plot for target time-
frame for screenings set in the national guidelines. The
dates were assumed as 15th of each month. A target time-
frame for screening was set at 1 month after arrival for
CXR screening and at 3 months after arrival for syphilis
screening as per national guidelines [23].
Screening yields were presented as the proportion of
seropositive findings (numerator) out of all screenings
performed (denominator) stratified by age groups.
Laboratory diagnostics
Serum hepatitis B surface antigen (HBsAg) and serum HIV
antigen and antibodies (HIVAg/Ab) were determined using
chemiluminescence microparticle immunoassays (CMIA)
(ARCHITECT® i1000SR or i2000SR HIVAg/Ab Combo and
ARCHITECT® i1000SR or i2000SR HBsAg qualitative re-
spectively, Abbot, Chicago, Illinois, USA). HIVAg/Ab posi-
tive findings were confirmed with an immunoblot assay in
the reference laboratory (TYKSLAB, Turku, Finland or
HUSLAB, Helsinki, Finland). Serum Treponema pallidum
antibodies (anti-Trpa) were determined using CMIA
(IMMULITE® 2000XPi, Siemens, Munchen, Germany or
ARCHITECT® i2000SR, Abbot). The blood lymphocyte re-
activity to Mycobacterium TB antigens was determined
using an Interferon Gamma Release Assay (IGRA) (Quanti-
FERON-TB Gold Plus, Qiagen, Hilden, Germany). Positive
cases were referred to a doctor’s consultation.
Statistical considerations
The data analysis was performed using Microsoft Excel
2010 (Microsoft, Redmont, Washington, USA). The con-
fidence intervals (CI) were calculated according to Wald.
Pearson’s Chi-squared was used to test the null hypoth-
esis and p-values of 0.05 or below was considered statis-
tically significant. Median and average dates of arrival
and screening are presented. Average delay to screening
was considered as the difference in means of arrival and
screening after assuming that E(x-y) = Ex - Ey where E is
the expected value and a linear operator. The study was
endorsed by the Research Ethical Committee of the Na-
tional Institute for Health and Welfare (§758, 16.3.2017).
Results
A total of 38,134 individuals sought asylum in Finland
during 2015–2016. Due to missing information regard-
ing their nationality, 520 (1.4%) individuals were ex-
cluded from analyses. Accurate information on the
number of asylum seeking children was available; all
other individuals, including the 190 (0.5%) individuals
with missing information on age, were assumed to be
adults. Of the 37,614 asylum seekers included in the
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final study population, one in four (24.0%, n = 9031) of
the applicants were under 18 years of age, 37.6% (n =
3400) of whom were unaccompanied by a guardian. The
majority of applicants were young adult men in the age
group of 18 to 34 years (Table 2).
Prevalence of eligibility
Of the asylum seekers included in the study population,
91.8% [95% CI 91.5–92.0%] were eligible for TB screen-
ing and 95.2% [95.0–95.5%] for hepatitis B, HIV or syph-
ilis. There were no significant differences in screening
eligibility between children and adults for either CXR or
blood screenings (p = 0.89 and 0.81, respectively).
Coverage of screening
The overall coverage of CXR screening among eligible
adults and children was 71.6% [95% CI 71.1–72.0%],
with 25,048 examinations performed. CXR screening
was performed for 19,390 adults and 5658 for children.
The CXR coverage among adults was 72.9% [72.4–
73.5%] and among children 67.2% [66.2–68.2%] (p < 0.01
between age groups). The overall coverage of syphilis
screening was 60.6% [60.1–61.1%], with 22,016 tests per-
formed for those eligible for screening. Anti-Trpa tests
were performed for 16,671 adults and 5345 children.
The coverage of syphilis screening was 60.4% [59.8–
60.9%] among adults and 61.4% [60.4–62.5%] among
children (p = 0.26 between age groups).
Fig. 1 Cumulative absolute number of chest X-ray (a) and anti-Trpa screenings (b) performed in 2015–2016 in comparison to cumulative
absolute number of arrival of screening eligible asylum seeking children and adults
Fig. 2 Cumulative relative proportion of performed chest X-ray (a) and anti-Trpa screenings (b) out of all screenings performed by month in
2015–2016 against the target timeframes for screenings for children and adults
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Timing of screening
Median date of asylum appeal was September 2015 for
adults and October 2015 for children. Median date of
CXR screening was December 2015 for both adults and
children. Median date anti-Trpa screening was January
2016 for adults and December 2015 for children. Com-
parison of the cumulative absolute numbers of arrivals
to the absolute numbers of screenings performed shows
how the screening coverage changed over time (Fig. 1).
Cumulative absolute number of arrival of screening eli-
gible asylum seeking children and adults plateaued by
beginning of 2016 due to decreasing number of new ap-
plications (Fig. 1). The cumulative absolute number of
CXR (Fig. 1a) and anti-Trpa screenings (Fig. 1b) per-
formed in 2015–2016 plateaued later in May–July 2017.
The estimated average delay from arrival to CXR
screening among those who were screened was 74 days
for adults and 43 days for children. The average delay to
syphilis screening was 91 days among screened adults
and 47 days among screened children. Comparison of
the cumulative relative proportion of performed screen-
ings out of all screenings performed by month in 2015–
2016 against target timeframes depicts the delays in
screenings (Fig. 2). For adults, the CXR screenings were
delayed vis-à-vis the target timeframe from September
2015 to October 2016 (Fig. 2a). For children, the CXR
screenings began to lag in September 2015, but were
already back on schedule by April 2016. Anti-Trpa
screening of adults was delayed from November 2015
until July 2016, but children’s screenings remained on
schedule throughout the follow-up period (Fig. 2b).
No differences in timing of CXR or syphilis screening
among children were observed between the two service
providers. However among adults, both CXR and syph-
ilis screenings were performed later (median March
2016 and May 2016 respectively) by the provider serving
the Helsinki metropolitan area in comparison to the pro-
vider serving the rest of Finland (median December
2015 for both CXR and syphilis screening respectively).
Prevalence of infections
Based on the screening results, we estimated the prevalence
of infectious diseases among the study population. The over-
all HBsAg prevalence was 1.4% [95% CI 1.3–1.6%]. HBsAg
prevalence was significantly higher among adults (1.6%, 95%
CI 1.4–1.8%, n= 274) than among children (0.8%, 95% CI
0.6–1.1%, n= 44) (p < 0.01). Ten HBsAg-positive cases were
identified in children less than 15 years of age.
The overall HIV prevalence was 0.3% [95% CI 0.1–0.4%,
n = 45] with no cases in children. The total prevalence of
positive syphilis serology was 1.0% [95% CI 0.8–1.1%]. The
prevalence of syphilis serology among adults (1.2%, 95%
CI 1.0–1.4%, n = 199) was significantly higher than among
children (0.2%, 95% CI 0.1–0.4%, n = 12) (p < 0.01). Four
Table 2 Basic characteristics of the asylum seekers to Finland in 2015–2016
Characteristic 2015; n (%),
total n = 32,477
2016; n (%),
total n = 5657
Total; n (%),
total n = 38,134
Age at asylum appeal, yearsa
0–13 4250 (13.1) 1419 (25.1) 5669 (14.9)
14–17 3402 (10.5) 338 (6.0) 3740 (9.8)
18–34 19,585 (60.3) 2812 (49.7) 22,397 (58.7)
35–64 4995 (15.4) 1029 (18.2) 6024 (15.8)
65 or above 78 (0.2) 36 (0.6) 114 (0.3)
Menb 26,424 (81.4) 3698 (65.4) 30,122 (79.0)
Originc
Iraq 20,484 (63.1) 1247 (22.0) 21,731 (57.0)
Afganistan 5214 (16.1) 757 (13.4) 5971 (15.7)
Somalia 1981 (6.1) 432 (7.6) 2413 (6.3)
Syria 877 (2.7) 602 (10.6) 1479 (3.9)
Other Middle East and North Africa 1235 (3.8) 813 (14.4) 2048 (5.4)
Europe 1060 (3.3) 203 (3.6) 1263 (3.3)
Sub-Saharan Africa 545 (1.7) 576 (10.2) 1121 (2.9)
Asia 311 (1.0) 493 (8.7) 804 (2.1)
Former Soviet Union Countries 373 (1.1) 351 (6.2) 724 (1.9)
Other 29 (0.1) 31 (0.5) 60 (0.2)
aFor 190 individuals (0.5%), the age at immigration was missing. bFor 55 (0.1%) individuals, information on the sex was missing. cOrigin is based on nationality.
Nationality was unknown for 383 (1.0%) individuals and 137 (0.4%) applicants had no nationality
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anti-Trpa positive cases were identified in children less
than 15 years of age. Only one IGRA-positive case was
identified in a child less than 7 years old, with the preva-
lence being 0.6% [95% CI 0–0.8%].
Comparison of prevalence rates between the two ser-
vice providers and between different years indicated that
HIV prevalence was significantly higher in data reported
by the provider operating in the Helsinki metropolitan
area compared to the provider serving the rest of the
country (1.5 and 0.1% respectively, p < 0.01). Prevalence
of HIV and anti-Trpa positivity was significantly lower in
2015 (0.2 and 0.7% respectively) as compared to 2016
(0.5 and 1.2% respectively, p < 0.05). We did not observe
differences in reported prevalence rates of HBsAg,
anti-Trpa nor IGRA between service providers nor in
different years.
Discussion
We described the public health response to the large in-
flux of asylum seekers to Finland during 2015–2016 by
evaluating the implementation and timing of infectious
disease screenings using healthcare procurement data.
As a contrast to other studies performed in healthcare
settings [19, 20] or in selected regions of destination
countries [16–20, 25–28], our study included an national
asylum seeker population, which reinforces the external
validity of our results. Due to the service providers’ fi-
nancial interests, the healthcare procurement data are
likely to be accurate, available and internally valid. In
Finland, the asylum seekers’ health services were
contracted out to only two national service providers,
which facilitated the data collection.
Screening coverage
Similar to findings from a recent systematic review on
coverage of infectious disease screening among migrants
[29], the screening coverage of pulmonary TB and hepa-
titis B, HIV and syphilis among asylum seekers to
Finland during 2015–2016 remained modest. The large
influx of asylum seekers to Finland during this time
stretched the health system’s capacity, especially in the
areas of most frequent border crossings and the transit
centre locations – at the Northern border between
Finland and Sweden (Tornio) and Helsinki metropolitan
area. Facing this pressure, some sub-national health au-
thorities decided to limit the scope or delay infectious
disease screenings services for asylum seekers as op-
posed to national guidelines [30]. Therefore, the ob-
served deficits in coverage can result from regional
differences in screening practices.
The significantly higher CXR screening coverage for
adults than children can be explained by the fact that in
clinical practice, adults with suspicion of a lower respira-
tory tract infection are more likely to be referred to a
diagnostic CXR than children. Moreover, to support this,
blood screening coverage between children and adults did
not differ. As a study limitation, procurement data do not
differentiate the indication of a test, therefore, the total
number of CXRs also includes diagnostic X-rays.
Timing of the response
The monthly accumulation of the number of screening tests
in comparison to the number of asylum applications from
screening-eligible countries shows that the intensity of
screening for pulmonary TB, hepatitis B, HIV and syphilis
began to lag as the number of arriving asylum seekers in-
creased exponentially in September 2015 (Fig. 1). The accu-
mulation of both arrivals and screenings plateaued by May–
July 2016. This stagnation in the cumulative number of new
asylum applications is explained by the decreasing number
of arrivals to Finland in spring 2016. However, the simultan-
eous plateau in cumulative number of screenings performed
suggests structural reasons for suboptimal coverage.
Children arrived slightly later to Finland, compared to
adults, but were screened earlier (Fig. 2). The average delay
from arrival to CXR screening exceeded the timeframe set
in the national guidelines (1 month) for both adults
(74 days) and children (43 days) [23]. However, for children,
the delay from arrival to blood screening (47 days)
remained within the target timeframe (3 months). The
average delay in screening was almost twice as long for
adults than for children for both CXR and anti-Trpa
screening. Considering the high number of individuals in
our data, the result is likely to be highly significant although
we are unable to tests the statistical significance. The ob-
served prioritisation of children as a vulnerable population
is in accordance with national guidelines [23], international
agreements [9] and healthcare ethics.
Among adults, CXR and blood screening were delayed
especially in Helsinki metropolitan region which might
reflect the impact of the sub-national guidelines [30].
However, we are not able to assess the average delay
from arrival to screening between the two service pro-
viders due lacking information regarding the region in
the immigration data.
In general, delays in the implementation of screening re-
flect the capacity of the healthcare system to respond to
sudden changes, in this case, to a large increase in the de-
mand for services. Considering that up to one third of asy-
lum seekers were not reached by screening, the presented
delays are likely to be underestimates. A delay in screening
might result in longer periods of infectiveness, increased
morbidity and possible transmission of the disease [1].
To best of our knowledge, the only other study to evalu-
ate the delay from arrival to implementation of infectious
disease screening during the European migrant crisis in
2015–2016 was reported from Sweden [21]. While in the
Sweden a majority of the unaccompanied asylum seeker
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children had arrived by January 2015, 96% of the referrals
were received before June 2016 suggesting a delay from
arrival to screening of approximately 5 months.
Infectious disease prevalence
The observed HBsAg seroprevalence of 1.4% was lower as
compared to majority of previous studies among asylum
seeker in Europe [17, 18, 20, 25–28, 31]. A hepatitis B sero-
prevalence study among adult asylum seekers from
Middle-East and Horn of Africa in the Netherlands in 2016
concluded a lower HBsAg prevalence of approximately 1%
as compared to our study [32]. Differences in seropreva-
lence rates are most likely due to differences in countries of
origin and age distributions among the recently-arrived asy-
lum seeker populations. In our sample, the proportion of
asylum seekers from Sub-Saharan Africa and Asia shown
to have highest risk for hepatitis B, was low [33]. On the
other hand, Syrian migrants have been shown to have low
HBsAg prevalence [19, 27], but Syrians represented only a
clear minority in our study population. The observed HIV
prevalence of 0.3% was lower or comparable to other stud-
ies among asylum seekers to Europe during the migrant
crisis in 2015–2016 [16, 20, 25–28, 31].
Estimates of syphilis seroprevalence among asylum seekers
in Europe in 2015–2016 are sparse and vary according diag-
nostic tests used. The 1.0% seroprevalence of anti-Trpa posi-
tivity in our study was higher or comparable as shown in
previous studies with a similar population tested with the
same diagnostic methods [16, 31]. Anti-Trpa positive cases
were referred to a doctor’s consultation and further diagnos-
tics were performed to determine whether a case represented
active syphilis requiring treatment or whether positivity was
due to a previously-treated infection and was thus an im-
munological scar. More information is needed to understand
the socio-demographic risk factors and clinical features of
the anti-Trpa positive cases. Having said this, the results on
syphilis prevalence support the inclusion of anti-Trpa screen-
ing in the national guidelines.
The low prevalence of IGRA positivity among children
less than 7 years of age not vaccinated with BCG can be
explained by the selected population.
A higher HIV prevalence was reported by the provider
serving the Helsinki metropolitan area which might re-
sult from heterogenous distribution of asylum seekers of
different origins in Finland. From our data, we were un-
able to assess the specific location of testing and it’s in-
fluence on timing fo screening. Differences in HIV and
anti-Trpa prevalence observed between 2015 and 2016
can be explained by differences in countries of origin
among the asylum seekers (Table 2).
Limitations
Using healthcare procurement data instead of individual
level data resulted in an inability to evaluate the
influence of socio-demographic background, previous
patient history, or concurrency of infections. It was also
not possible to assess regional differences or, on an indi-
vidual level, screening coverage or screening delays.
Additionally, we were unable to assess the screening
yields of TB, since all suspected cases are referred to ter-
tiary level care for further examinations. Prevalence esti-
mations are affected by a selection bias as infection
prevalence might differ between asylum seekers who
participated in the screenings as opposed to those who
did not.
Factors contributing to the possible underestimation of
the screening coverage are three-fold. Firstly, some asylum
seekers might have left the country before the screenings
were performed. The average duration of the asylum
process has been estimated to be between 6 and 24 months
[34], hence, the number of aborted appeals prior to infec-
tious disease screening and their contribution to the under-
estimation of the screening coverage is likely to be small.
Secondly, we obtained screening data from the two
nationally-contracted healthcare providers, but some re-
ception centres might have procured their services from
third party providers. Because the contracted service
providers can easily be reached from the vast majority of
reception centres, the proportion of services procured
from third party healthcare providers is likely to be
small. Thirdly, we were unable to assess the acceptability
of screening. However, in a recent systematic review
among asylum seekers in Europe, acceptability of screen-
ing has been shown to be high [29].
There are also important structural delays to consider,
from arrival to screening (up to 3 months) and from
screening to financial reporting (up to 2 months). Due
to these structural delays, our data include screenings
performed for asylum seekers who have arrived in late
2014 and excludes screenings of those who arrived in
late 2016. However, since the numbers of asylum appli-
cations in the second half of 2014 and 2016 were similar,
the effect on our analysis is likely to be very small.
Conclusions
Evaluations of screening programs should consider dimen-
sions of validity, reliability, yield, cost, acceptance and avail-
ability of follow-up services [7]. Our study adds to the sparse
evidence that the effectiveness of a screening program might
be compromised in real world conditions especially in a time
of a crisis [35, 36]. Barriers to achieving high coverage of in-
fectious disease screening among asylum seekers should be
recognized and addressed [29].
Debate on the infectious disease risks to public health
has accompanied the migrant crisis in Europe. The debate
is fuelled from one side with fear of spread of infectious
diseases and doubts on the cost-effectiveness of screening
on the other [37]. Austerity measures adopted by some
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countries in Europe restrict asylum seekers’ access to ser-
vices and increased risks to infectious disease hazards
[36]. Public health authorities have taken a clear stance on
asylum seekers being vulnerable to infections themselves
rather than generating a public health threat [37–39].
The large influx of asylum seekers to Finland in 2015–
2016 put the health system under pressure; the imple-
mentation of infectious disease screening was delayed in
comparison to the national guidelines and the overall
screening coverage remained sub-optimal. Results dem-
onstrate that asylum-seeking children, as a vulnerable
population, were prioritised in healthcare. Recognising
the modest screening coverage during the asylum
process, completion of screening and infectious disease
risks should be reassessed at contacts to healthcare dur-
ing residency and integration to ensure a higher screen-
ing coverage.
Infectious disease screening is an important dimension
of the public health response to a large influx of mi-
grants. In the current global political, ecological and
economic climate, continued migration is likely. How-
ever, in order to describe the effectiveness of the re-
sponse as a whole, more information is needed on the
resources, morbidity, usage of healthcare services, and of
alternative response strategies. Infectious disease control
measures should be ethically justified especially when
targeting marginalized populations such as asylum
seekers [6]. We need to draw lessons from the diverse
responses of the European migrant crisis of 2015–2016
and develop evidence-based approaches to ensure better
public health emergency preparedness in the future.
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